Literature DB >> 18090552

A cross-national study of the persistence of antihypertensive medication use in the elderly.

Boris L G van Wijk1, William H Shrank, Olaf H Klungel, Sebastian Schneeweiss, M Alan Brookhart, Jerry Avorn.   

Abstract

INTRODUCTION: Little is known about cross-national comparisons of the persistence of antihypertensive medication treatment, trends in persistence, and factors associated with persistence. The aim of this study was to describe and compare patterns of use of antihypertensive drugs in a population of elderly patients in the United States (Pennsylvania), Canada (British Columbia) and the Netherlands.
METHODS: A retrospective cohort study of Medicare enrollees in a state pharmacy assistance programme in Pennsylvania (USA), residents from British Columbia (Canada) and residents from the Netherlands registered in the PHARMO database was conducted. Each population included patients 65 years and older who were initiated on blood pressure-lowering treatment between 1 January 1998 and 31 December 2003 and who had continuous follow-up for at least 365 days. In these populations, the proportion of patients with at least 180 consecutive days without medication available (non-persistence) were identified as were predictors of non-persistence using Cox proportional hazards.
RESULTS: A total of 9664 Medicare enrollees (USA), 25 377 residents from British Columbia and 24 603 residents from the Netherlands were evaluated. During the first year after the initiation of treatment, the percentage of patients with at least 180 days without medication was 23.3% in Pennsylvania, 23.4% in British Columbia and 24.0% in the Netherlands. After 6 years, these percentages increased to 41.1, 36.3 and 38.2%, respectively. Factors associated with non-persistence were different between the three countries.
CONCLUSION: Despite differences in factors associated with persistence, non-persistence patterns are strikingly similar in all three populations. This suggests that the problem of non-persistence transcends international boundaries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090552      PMCID: PMC2745820          DOI: 10.1097/HJH.0b013e32826308b4

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  42 in total

Review 1.  Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia.

Authors:  P K Whelton; J He; P Muntner
Journal:  J Hum Hypertens       Date:  2004-08       Impact factor: 3.012

2.  The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen.

Authors:  Boris L G Van Wijk; Olaf H Klungel; Eibert R Heerdink; Anthonius de Boer
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

Review 3.  A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue.

Authors:  Héloise Cardinal; Amir Abbas Tahami Monfared; Marc Dorais; Jacques LeLorier
Journal:  Can J Cardiol       Date:  2004-03-15       Impact factor: 5.223

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

6.  Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing".

Authors:  J Avorn; S B Soumerai
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

7.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.

Authors:  P W Choo; C S Rand; T S Inui; M L Lee; E Cain; M Cordeiro-Breault; C Canning; R Platt
Journal:  Med Care       Date:  1999-09       Impact factor: 2.983

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  Medicaid data as a resource for epidemiologic studies: strengths and limitations.

Authors:  R A Bright; J Avorn; D E Everitt
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

View more
  17 in total

1.  Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up of 78,453 incident users.

Authors:  Randi Selmer; Hege Salvesen Blix; Knud Landmark; Asmund Reikvam
Journal:  Eur J Clin Pharmacol       Date:  2012-03-18       Impact factor: 2.953

2.  Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals.

Authors:  Brandon K Bellows; Natalia Ruiz-Negrón; Kirsten Bibbins-Domingo; Jordan B King; Mark J Pletcher; Andrew E Moran; Valy Fontil
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-06-05

3.  Persistence to antihypertensive drug treatment in Swedish primary healthcare.

Authors:  Miriam Qvarnström; Thomas Kahan; Helle Kieler; Lena Brandt; Jan Hasselström; Kristina Bengtsson Boström; Karin Manhem; Per Hjerpe; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.953

4.  Meta-analysis: impact of drug class on adherence to antihypertensives.

Authors:  Ian M Kronish; Mark Woodward; Ziad Sergie; Gbenga Ogedegbe; Louise Falzon; Devin M Mann
Journal:  Circulation       Date:  2011-04-04       Impact factor: 29.690

5.  Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases.

Authors:  Marsha A Raebel; Julie Schmittdiel; Andrew J Karter; Jennifer L Konieczny; John F Steiner
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

6.  Persistence profile to nucleos(t)ide analogue treatment for patients with chronic hepatitis B.

Authors:  Yolanda Borrego Izquierdo; Encarnación Gómez Fernández; Patricia Monje Agudo; Rocío Jiménez Galán; Carmen V Almeida-González; Mónica Ferrit Martín; Ramón Morillo Verdugo
Journal:  Eur J Hosp Pharm       Date:  2016-02-22

7.  Persistence with Antihypertensive Medications in Uncomplicated Treatment-Naïve Patients: Effects of Initial Therapeutic Classes.

Authors:  Young-Mi Ah; Ju-Yeun Lee; Yun-Jung Choi; Baegeum Kim; Kyung Hee Choi; Jisun Kong; Jung Mi Oh; Wan Gyoon Shin; Hae-Young Lee
Journal:  J Korean Med Sci       Date:  2015-11-30       Impact factor: 2.153

8.  Proportion and risk indicators of nonadherence to antihypertensive therapy: a meta-analysis.

Authors:  Mark Lemstra; M Wasem Alsabbagh
Journal:  Patient Prefer Adherence       Date:  2014-02-13       Impact factor: 2.711

9.  Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study).

Authors:  Gianfranco Parati; Stefano Omboni; Angelo Compare; Enzo Grossi; Edward Callus; Achille Venco; Maurizio Destro; Giuseppe Villa; Paolo Palatini; Enrico Agabiti Rosei; Simonetta Scalvini; Stefano Taddei; Dario Manfellotto; Stefano Favale; Carmine De Matteis; Michele Guglielmi; Laura Lonati; Francesco Della Rosa; Ellen Tosazzi; Anna Maria Grandi; Andrea Maria Maresca; Christian Mongiardi; Micaela Mare; Alessandra Rossi Ricci; Francesca Cagnoni; Joannhe Georgatos; Valeria Besostri; Viviana Ferrari; Ombretta Omodeo; Francesca Dorigatti; Elisa Bonso; Chiara Guarnieri; Lorenza Muiesan; Anna Paini; Deborah Stassaldi; Angelo Cinelli; Palmira Bernocchi; Silvana Rocchi; Armando Magagna; Lorenzo Ghiadoni; Irene Del Frate; Francesca Boresi; Antonella Guidi; Maria Antonietta Re; Luisa Pellicciotti; Antonia Florio; Giuliana Morani; Silvana Di Lillo; Antonietta Ambrosio; Antonio Casciello; Maria Quaglia; Cinzia Forleo; Maria Annunziata Ardito; Stefania Gerunda; Mariligia Panunzio
Journal:  Trials       Date:  2013-01-23       Impact factor: 2.279

10.  Discontinuation of anti-hypertensive drugs increases 11-year cardiovascular mortality risk in community-dwelling elderly (the Bambuí Cohort Study of Ageing).

Authors:  Maria Lea Correa Leite; Joselia O A Firmo; Antonio Ignacio Loyola Filho; Maria Fernanda Lima-Costa
Journal:  BMC Public Health       Date:  2014-07-16       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.